Sinovac Clarifies Position on Restructuring Involving Its Chinese Subsidiary
Wednesday January 31, 8:30 am ET
BEIJING, Jan. 31 /PRNewswire-FirstCall/ -- Sinovac Biotech Ltd. (Amex:
SVA -
News; the "Company") noted today that China Bioway Biotech Group Co., Ltd. ("China Bioway"), a 28.44% minority shareholder in its 71.56% PRC subsidiary, Sinovac Biotech Co., Ltd. ("Sinovac China"), has recently received approvals from the PRC Ministry of Education and the PRC Ministry of Commerce to restructure China Bioway's equity interest in Sinovac China. The proposed restructuring contemplates China Bioway transferring its equity interest to an offshore company and eventually exchanging this equity interest for shares in the Company.
In response to investors' inquiries concerning the restructuring, the Company confirmed today that it had explored with China Bioway the possibility of the Company's acquisition of China Bioway's minority interest in Sinovac China. However, the Company has not commenced any formal negotiation or entered into any definitive agreement with China Bioway. Sinovac will comply with all applicable laws, rules and regulations (including U.S. securities laws and AMEX rules) and will obtain all necessary approvals (including any necessary shareholders' approval) in connection with any such acquisition, if it were to materialize.
About Sinovac
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's vaccines include Healive(TM) (hepatitis A), Bilive(TM) (combined hepatitis A and B) and Anflu(TM) (influenza). Sinovac is currently developing human vaccines against the H5N1 strain of pandemic influenza, Japanese encephalitis and SARS. Additional information about Sinovac is available on its website,
http://www.sinovac.com. To be added to our distribution list, please email:
info@sinovac.com.
Safe Harbor Statement
This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward- looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.
Contact Information:
Helen G. Yang
Sinovac Biotech Ltd.
Phone: 10-82890088 Ext. 871
Fax: 10-62966910
Investors/Media:
Stephanie Carrington/Janine McCargo
The Ruth Group
(646) 536-7017/7033
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a global biopharmaceutical company headquartered in China. Guided by its mission to “Supply Vaccines to Eliminate Human Diseases,” the Company is dedicated to the research, development, manufacturing and supply of vaccines and related biological products, providing vaccine products and related solutions for disease prevention and control worldwide.
SINOVAC has a diversified vaccine portfolio across multiple disease areas, including influenza, viral hepatitis, varicella, hand, foot and mouth disease (HFMD), poliomyelitis, rabies, tetanus, and pneumococcal disease. Three of SINOVAC's vaccines have been prequalified by the World Health Organization: the inactivated hepatitis A vaccine Healive®, the Sabin-strain inactivated poliomyelitis vaccine (sIPV), and the live attenuated varicella vaccine.
SINOVAC has extensive experience in vaccine research, development and commercialization for emerging infectious diseases and public health emergencies. The Company initiated vaccine R&D in response to major public health threats, including SARS, H5N1, H1N1, and COVID-19, and developed the world's first inactivated SARS vaccine (with Phase I clinical trials completed), China's first inactivated pandemic influenza vaccine against H5N1 (Panflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the world's most widely used inactivated COVID-19 vaccine. Beyond its marketed portfolio, SINOVAC continues to advance its R&D pipeline, spanning combination vaccines, recombinant protein vaccines, mRNA technologies, antibody-based products, and other next-generation technologies and product platforms, while expanding its capabilities in disease prevention and biopharmaceuticals.
With a long-standing commitment to innovation and global health, SINOVAC continues to deepen collaboration with research institutions, international organizations, and local partners while expanding its global presence. Through technological collaboration, localized production, and industrial partnerships, the Company aims to improve access to high-quality vaccines across regions, better address local disease prevention and healthcare needs, and strengthen preparedness for future public health challenges.
For more information, please see the Company's website at www.sinovac.com.
EN
